Insider Selling: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells 7,351 Shares of Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 7,351 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $95,563.00. Following the sale, the insider now directly owns 232,681 shares of the company’s stock, valued at $3,024,853. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Thomas Gad also recently made the following trade(s):

• On Tuesday, May 21st, Thomas Gad sold 25,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $300,000.00.

Y-mAbs Therapeutics Trading Down 1.5 %

Shares of YMAB stock opened at $12.22 on Friday. Y-mAbs Therapeutics, Inc. has a 12 month low of $4.60 and a 12 month high of $20.90. The company’s fifty day moving average price is $14.61 and its two-hundred day moving average price is $11.72.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. The firm had revenue of $23.36 million for the quarter, compared to analyst estimates of $21.72 million. On average, analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.45 EPS for the current year.

Wall Street Analysts Forecast Growth

YMAB has been the topic of several recent research reports. BMO Capital Markets lifted their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a report on Monday, March 4th. Canaccord Genuity Group lifted their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 4th. HC Wainwright lifted their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, May 13th. Finally, Wedbush restated an “outperform” rating and set a $18.00 target price (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $17.33.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. lifted its holdings in Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after buying an additional 1,056 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $34,000. Tower Research Capital LLC TRC raised its stake in shares of Y-mAbs Therapeutics by 345.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,686 shares of the company’s stock valued at $46,000 after purchasing an additional 5,185 shares in the last quarter. Bailard Inc. acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $115,000. Finally, Caxton Associates LP acquired a new stake in shares of Y-mAbs Therapeutics in the 1st quarter valued at about $306,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.